ITGAM and acute myeloid leukemia: Results of the meta-analysis showed that ITGAM positivity was associated with lower complete remission rate (OR = 0.44; 95% CI, 0.25–0.79; p = 0.006) and shorter OS (HR = 0.66; 95% CI, 0.55–0.80; p < 0.0001), Consistent with our analysis, ITGAM positivity predicts a poor prognosis of AML patients.